Hemoglobinopathies such as sickle cell disease and β-thalassemia are among the most common inherited blood disorders worldwide. For countries like Greece and across the Mediterranean, where these conditions are still highly prevalent, early detection and prevention are critical to reducing disease burden and improving quality of life.
At The Science Support, we work with leading partners such as Revvity to bring laboratories reliable, high-performance in vitro diagnostic (IVD) solutions designed to detect hemoglobinopathies accurately and efficiently — from newborn screening to parental carrier testing.
Why Early Detection of Hemoglobinopathies Matters
Early diagnosis of hemoglobinopathies is not only about identifying disease — it’s about enabling timely intervention, prevention, and informed decision-making for families.
For Newborns: Newborns with hemoglobin disorders often show no immediate symptoms due to high levels of fetal hemoglobin (Hb F), which can mask the presence of pathological variants. Early screening enables timely detection of sickle cell anemia and β-thalassemia major, ensuring appropriate monitoring and treatment from the start.
For Parents: Carrier detection helps identify individuals at risk of passing on the disease to their children. Integrating carrier testing into genetic counseling and family planning programs supports prevention and reduces disease prevalence in future generations.
Revvity’s RESOLVE™ Hemoglobin Kit used together with the Migele™ Electrophoresis Unit provides laboratories with a robust, scalable platform for hemoglobin variant analysis.
- Flexible Sample Formats: Compatible with whole blood, cord blood, or dried blood spots (DBS), this system is ideal for both routine diagnostics and large-scale newborn screening programs.
- High Specificity and Sensitivity: Using Isoelectric Focusing (IEF) , the system achieves superior separation and resolution of clinically relevant hemoglobins, allowing precise differentiation between variants.
Key advantages include:
- Clear distinction of Hb F from Hb A, differentiating sickle cell anemia (Hb SS) from sickle cell trait (Hb AS).
- Accurate separation of Hb C, Hb A2, and Hb E, as well as rare forms such as Hb D-Los Angeles, Hb G-Philadelphia, and Hb Lepore from Hb S.
- Detection of minor variants such as Hb Bart’s in newborns and Hb Constant Spring in adults.
- Scalable, Fast Workflow: With results available in 60–90 minutes, laboratories can achieve high throughput without compromising precision. Multiple Migele™ units can run in parallel using a single water bath, while the JB-2 staining system enhances visibility and interpretability of hemoglobin bands.
Real-World Impact for Families
In Greece, β-thalassemia continues to affect many families, making reliable hemoglobinopathy screening an essential part of national healthcare programs. By enabling accurate detection at both the newborn and parental levels, Revvity’s RESOLVE™ + Migele™ solution supports early intervention, prevention, and informed reproductive choices — helping to reduce disease transmission and improve long-term outcomes.
A Partnership for Diagnostic Laboratories
At The Science Support, we are proud to deliver Revvity’s proven technologies to diagnostic laboratories — combining innovation, accessibility, and precision to advance hemoglobinopathy detection and prevention.
Contact us at sales@thesciencesupport.com to discuss how you can integrate Revvity’s RESOLVE™ + Migele™ IVD systems into your laboratory workflow for best results. Find out more about our complete portfolio of solutions for advanced and early detection of crucial disorders in newborn screening.
References
- Revvity Hemoglobinopathy Screening Solutions
- Weatherall, D. J., & Clegg, J. B. (2001). The Thalassaemia Syndromes. Blackwell Science.
- Modell, B., & Darlison, M. (2008). Global epidemiology of haemoglobin disorders and derived service indicators. Bulletin of the World Health Organization, 86(6), 480–487.